Quintiles shutters Phase I unit in India

By Zachary Brennan

- Last updated on GMT

Related tags Pharmacology Clinical trial

Quintiles has closed its Phase I ops in India
Quintiles has closed its Phase I ops in India
CRO Quintiles has decided to close its Phase I unit in Hyderabad, India, because of a “challenging external business environment,” a company spokesman told us.

The decision came from the Board of Directors of Quintiles’ joint venture with Apollo Hospitals Enterprise, which decided to close the operation on September 30, 2013, Phil Bridges, Quintiles spokesman, told Outsourcing-Pharma.com. 

All employees of the Phase I Hyderabad Unit who opted to continue their careers with Quintiles were absorbed in our other businesses​,” Bridges said. “The decision has not impacted the rest of our business in India or our Early Clinical Development operations elsewhere in the world​.” 

According to India’s CDSCO​ (Central Drugs Standards Control Organization), which recently released a list of all of the clinical trials that were under review in the country, Quintiles is currently running four clinical trials for sponsors Otsuka, AstraZeneca and Roche. 

And Quintiles seems confident that its early phase development services will not be hampered by the unit’s closure. 

We continue to operate our clinical pharmacology units in London and Overland Park, Kansas, as well as partner sites in the US, EU and Asia​,” Bridges added. 

Clinical Trial Issues in India​ 

But the decision for Quintiles to close its Phase I unit comes as many in the industry are seeing their trial work halted or delayed there. 

The Supreme Court of India recently called for all of the data supporting trial approvals​ made by CDSCO in July and August.  The action was spurred by an NGO’s petition requesting an inquiry on how only a limited number of adverse events and deaths during clinical trials were attributed to the trials. 

That request for data comes as the country is still trying to iron out its policies on compensating clinical trial patients​, and other ways to strengthen the regulation of clinical trials​.

Related news

Show more

Related products

show more

Automated metadata management in clinical trials

Automated metadata management in clinical trials

Content provided by Formedix | 01-Aug-2023 | White Paper

When it comes to efficient clinical study build, content is king. Most importantly: metadata content. In this blog, we explore the role of metadata in...

Small Molecule development – getting it right

Small Molecule development – getting it right

Content provided by Lonza Small Molecules | 20-Jun-2023 | Insight Guide

Small Molecule drug development is something more and more ambitious emerging pharmaceutical companies are taking on from end to end. But this path can...

Validate clinical study data with Formedix CORE

Validate clinical study data with Formedix CORE

Content provided by Formedix | 19-Jun-2023 | White Paper

In April 2023 at the CDISC Europe Interchange, we launched Formedix CORE, the first free-to-use, downloadable application encompassing the CDISC Open Rules...

Related suppliers

Follow us


View more